China’s Sinovac Biotech will trial its Covid-19 vaccine in children and adolescents in South Africa as part of a global Phase III study, Reuters reports.
In a statement the firm said that the study will evaluate the efficacy, immunogenicity and safety of the CoronaVac vaccine on children and adolescents aged 6 months to 17 years.
The global trial will enroll 14,000 participants across Chile, the Philippines, Malaysia, Kenya including 2,000 in South Africa.
South African drugs regulator Sahpra, has approved the trial and the first child will be vaccinated at the MeCRU Clinical Research Unit based at the Sefako Makgatho Health Sciences University on Friday (10 September).
“The primary objective of the study is to evaluate the efficacy of two doses of CoronaVac against confirmed symptomatic Covid-19 cases in children and adolescents. Efficacy will also be evaluated against hospitalisation and severe Covid-19,” Sinovac said.